Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Nasal cavity and paranasal sinus cancers (including esthesioneuroblastoma), drawn from the whole corpus: 1 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Late presentation: most tumours are locally advanced at diagnosis; awareness in ENT clinics and imaging AI are the response.
No randomised trials exist for any sinonasal histology; international consortia are pooling cases.
IDH2-mutant SNUC: prospective trials of IDH2 inhibitors.
Visual and neurocognitive toxicity of radiotherapy: protons and reduced-margin planning.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 9 changes by month →When this page itself was last checked or edited.
Induction platinum-etoposide; responders proceed to definitive chemoradiotherapy, non-responders to surgery plus radiotherapy (response-adapted approach, JAMA Oncol 2019).
Amit and colleagues, JAMA Oncol.
Dogan and colleagues; Jo and colleagues.
Series from Pittsburgh and Europe show equivalence to open surgery.
A milestone in how this cancer is treated.